

eISSN 2240-2683

Reumatismo - The Italian Journal of Rheumatology

<https://www.reumatismo.org/reuma>

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Early Access service lets users access peer-reviewed articles well before print/regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

Reumatismo is, therefore, E-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination, and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

The E-publishing of this PDF file has been approved by the authors.

Please cite this article as:

Buscetta G, Palumbo A, Rizzo C, Guggino G. **Successful treatment of refractory tracheal stenosis complicating anti-neutrophil cytoplasm antibody-associated vasculitis with sirolimus.** *Reumatismo* doi: 10.4081/reumatismo.2025.1851

Submitted: 29-01-2025

Accepted: 27-06-2025

 © the Author(s), 2025
Licensee PAGEPress, Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Successful treatment of refractory tracheal stenosis complicating anti-neutrophil cytoplasm antibody-associated vasculitis with sirolimus

Giorgio Buscetta, Antonino Palumbo, Chiara Rizzo, Giuliana Guggino

Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy

Correspondence: Giuliana Guggino, Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy.

Tel.: 00390916552148

E-mail: giuliana.guggino@unipa.it

Key words: vasculitis, autoimmune diseases, GPA, treatment.

Contributions: AP, GB, CR, planned and wrote the manuscript, and collected and critically revised data; AP, GB, followed the patient, collected data, and performed literature research; GG supervised the project and critically revised the manuscript. All authors read and approved the final version of the manuscript.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: not applicable.

Patient consent for publication: patient consent was obtained.

Availability of data and materials: all data are available from the corresponding author upon request.

Funding: none.

Summary

Laryngotracheal granulomatous inflammation is a clinical entity that may complicate either localized or systemic disorders. It can result in life-threatening airway compromise, requiring urgent medical or surgical intervention. We report the case of a patient presenting with recurrent tracheal stenosis secondary to anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis, refractory to conventional treatments. Despite multiple endoscopic dilatations and surgical resection of tracheal rings, disease control remained suboptimal. Introduction of sirolimus led to a sustained improvement of the stenotic lesion, as demonstrated by clinical and instrumental assessment. Sirolimus may be considered a valuable therapeutic option for severe subglottic inflammatory manifestations in ANCA-associated vasculitis.

Introduction

Subglottic stenosis of the laryngotracheal region is a consequence of inflammatory processes occurring in the upper airways. This condition may present as an isolated primary disorder or as a secondary complication of systemic diseases (1). In rheumatology, subglottic stenosis is most commonly associated with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis, such as granulomatosis with polyangiitis (GPA) and eosinophilic GPA, as well as with IgG4-related disease, particularly in pediatric patients, where it may represent the initial manifestation of the diseases (2-4). Other conditions linked to subglottic stenosis include inflammatory bowel diseases, such as Crohn's disease (5), and sarcoidosis (1). Regardless of the underlying cause, clinical manifestations include cough, stridor, dyspnea, exertional intolerance, obstructive sleep apnea, and, rarely, life-threatening airway obstruction (1, 6). Diagnosis requires endoscopic assessment with biopsies combined with laboratory investigations, including infectious serologies, inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), complete blood count, autoantibody screening, serum angiotensin-converting enzyme, urinary calcium, and lysozyme levels. Therapeutic endoscopic interventions include balloon dilatation, laser ablation, mucosal-sparing surgery, and local injection of glucocorticoids (GC) or mitomycin C, as well as stent placement (1, 7). Surgical management mainly consists of resecting the stenotic tract with subsequent end-to-end anastomosis or tracheostomy (1). Systemic treatments include GC, conventional synthetic disease-modifying anti-rheumatic drugs, *i.e.*, cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate, as well as biologic agents including rituximab (RTX), and targeted therapies like avacopan (6, 8).

Case Report

We report the case of a 33-year-old woman with recurrent tracheal stenosis secondary to GPA. The disease onset dated back to 2018 and was characterized by recurrent episodes of rhinosinusitis and otitis media. Laboratory tests revealed elevated perinuclear ANCA (p-ANCA) levels (418.7 U/L) by indirect immunofluorescence and anti-myeloperoxidase (MPO antibodies) >100 U/L by enzyme-linked immunosorbent assay. Serology for cytoplasmic ANCA (c-ANCA), anti-proteinase 3 (PR3), anti-nuclear antibodies, extractable nuclear antigen antibodies, rheumatoid factor, anti-citrullinated peptide antibodies, and anti-double-stranded DNA was negative. Infectious etiologies were excluded. A head computed tomography scan showed thickening of the nasal mucosa with marked deviation of the nasal septum. High-resolution computed tomography of the chest revealed no pulmonary involvement. Broncho-alveolar lavage was negative for infectious pathogens and showed no significant inflammatory cellularity. Hence, a diagnosis of ANCA-associated vasculitis, with predominant involvement of upper tract airways, was made. Although the serological profile was atypical for GPA, characterized by p-ANCA/MPO positivity rather than c-ANCA/PR3, this phenotype has been reported in approximately 20% of GPA patients and is thought to represent a distinct clinical subset (9-11). Shortly after diagnosis, the patient developed a severe tracheal stenosis. Initial treatment relied on endoscopic balloon dilatation coupled with intravenous methylprednisolone pulses (500 mg/day for 3 days), followed by oral prednisone (1 mg/kg/day), and subcutaneous methotrexate (15 mg/week). In February 2019, due to a life-threatening recurrence of the stenosis, a surgical resection of four tracheal rings with primary end-to-end anastomosis was performed. Histopathological analysis of the resected tissue demonstrated the presence of acute inflammation on a chronic background with granulomas and neutrophil infiltration. In April 2023, a new relapse of stenosis occurred. The patient was treated with a combination of avacopan (60 mg/day) and RTX (1000 mg at day 0 and 14), replacing previous ineffective treatment. Avacopan was discontinued in June 2023 due to secondary failure, while RTX was continued as maintenance therapy. In August 2023, sirolimus was introduced at 2 mg/day in combination with RTX (1000 mg every 6 months) and low-dose GC (PDN, 2.5 mg/day). Sirolimus blood level was regularly monitored, maintaining a therapeutic range of 5-9 ng/mL. The last endoscopic procedure, performed in September 2024, showed no new lesions. The residual tracheal stenosis remained stable with a luminal diameter of 9

mm, which allowed regular breathing (Figure 1). Radiological follow-up by computed tomography confirmed improvement and stability of the airway narrowing (Figure 2).

Discussion

Subglottic stenosis has been described in MPO-positive GPA patients (10, 11); to date, the experience with sirolimus to treat this complication is limited to a few case reports and small series. Poo *et al.* reported a case series of six patients with subglottic stenosis, five secondary to GPA and one to IgG4-related disease, who were treated with sirolimus. Of these, four patients continued long-term treatment, achieving GC discontinuation and a significant reduction in the frequency of endoscopic interventions (12). Samtani *et al.* described the case of a 13-year-old girl with upper airway obstruction due to idiopathic granulomatous inflammation of the glottis and supraglottis, unrelated to infectious or rheumatic diseases, that required continuous positive airway pressure (CPAP) for severe respiratory impairment. The patient showed inadequate response to both local and systemic GC, endoscopic procedures, and immunosuppressive drugs, such as mycophenolate mofetil and adalimumab. Ultimately, sirolimus was introduced with endoscopic reduction of oedema, improvement in exercise tolerance, and resolution of sleep apnea, with consequent CPAP discontinuation (13).

The rationale for using sirolimus in the case of subglottic stenosis is supported by *in vitro* studies that revealed a double anti-fibrotic effect. Indeed, sirolimus has been shown to reduce fibroblast proliferation and collagen production (14) and to inhibit T helper-17 cells expressing *mTOR*, preventing further activation of fibroblasts (15). Thus, sirolimus may exert both anti-fibrotic and anti-inflammatory effects, potentially interfering with key pathogenic processes causing the development and progression of subglottic stenosis.

Conclusion

The management of GPA-associated subglottic stenosis remains challenging, often requiring a combination of systemic and local therapeutic approaches that need further research to be optimized. Systemic immunosuppressive treatments are usually necessary to control active disease. In this regard, GC plus cyclophosphamide or RTX may induce clinical remission, particularly in cases of generalized vasculitic involvement (6, 16). Notably, RTX appears to reduce the risk of relapse compared to other agents (17, 18). Among alternative therapies, leflunomide has shown some efficacy in improving airway stenosis, while evidence on azathioprine, methotrexate, and mycophenolate mofetil remains limited (17).

Local interventions, such as endoscopic balloon dilatation with intra-lesional GC injection and topical mitomycin C, stand out as first-line options for subglottic stenosis management. In refractory cases, marked by extensive fibrosis, open transcervical surgery remains the definitive treatment, and tracheostomy may be necessary in life-threatening situations (19). Nevertheless, the current evidence is primarily anecdotal, based on isolated case reports and small series, and no consensus exists on a preferred treatment strategy. In this context, sirolimus emerges as a promising therapeutic option, warranting further investigation, in the management of GPA-related subglottic stenosis.

References

1. Aravena C, Almeida FA, Mukhopadhyay S, Ghosh S, Lorenz RR, Murthy SC, et al. Idiopathic subglottic stenosis: a review. *J Thorac Dis* 2020; 12: 1100-11.
2. Mokhtari TE, Miller LE, Jayawardena ADL, Sadow PM, Hardy SC, Rothman D, et al. Eosinophilic granulomatosis with polyangiitis: an unusual case of pediatric subglottic stenosis. *Laryngoscope* 2021; 131: 656-9.
3. Bach Á, Ambrus A, Iványi B, Tóbiás Z, Alim Marvasti GH, Rovó L. IgG4-related laryngeal disease as a possible cause of idiopathic subglottic stenosis: a case report. *Iran J Otorhinolaryngol* 2021; 33: 119-25.

4. Lee PY, Adil EA, Irace AL, Neff L, Son MBF, Lee EY, et al. The presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway. *Laryngoscope* 2017; 127: 233-40.
5. Colevas SM, Gietman BT, Cook SM, Kille TL. Granulomatous inflammation causing severe supraglottic edema and airway obstruction in a pediatric patient. *Ear Nose Throat J* 2022; 101: NP375-8.
6. Solans-Laqué R, Bosch-Gil J, Canela M, Lorente J, Pallisa E, Vilardell-Tarrés M. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. *Lupus* 2008; 17: 832-6.
7. Fijolek J, Wiatr E, Gawryluk D, Martusewicz-Boros MM, Orlowski TM, Dziedzic D, et al. Intratracheal dilation-injection technique in the treatment of granulomatosis with polyangiitis patients with subglottic stenosis. *J Rheumatol* 2016; 43: 2042-8.
8. Lebovics RS, Hoffman GS, Leavitt RY, Kerr GS, Travis WD, Kammerer W, et al. The management of subglottic stenosis in patients with Wegener's granulomatosis. *Laryngoscope* 1992; 102: 1341-5.
9. Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. *Am J Kidney Dis* 2020; 75: 124-37.
10. Monti S, Felicetti M, Delvino P, Padoan R, Berti A, Paolazzi G et al. Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis. *Clin Exp Rheumatol* 2021; 39: 107-13.
11. Schirmer JH, Wright MN, Herrmann K, Laudien M, Nölle B, Reinhold-Keller E et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener's) is a clinically distinct subset of ANCA-associated Vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. *Arthritis Rheumatol.* 2016; 68: 2953-63.
12. Poo SX, Pepper R, Onwordi L, Ghufloor K, Sandhu G, Salama A. Sirolimus use in patients with subglottic stenosis in the context of granulomatosis with polyangiitis (GPA), suspected GPA, and immunoglobulin G₄ -related disease. *Scand J Rheumatol* 2021; 50: 52-7.
13. Samtani P, Li M, Soma M, Teng A, Jacobson I, Banks C, et al. Idiopathic laryngeal granulomatosis in a teenage girl responsive to sirolimus. *Otolaryngology Case Reports* 2024; 31: 100599.
14. Namba DR, Ma G, Samad I, Ding D, Pandian V, Powell JD, et al. Rapamycin inhibits human laryngotracheal stenosis-derived fibroblast proliferation, metabolism, and function in vitro. *Otolaryngol Head Neck Surg* 2015; 152: 881-8.
15. Motz KM, Lina IA, Samad I, Murphy MK, Duvvuri M, Davis RJ, et al. Sirolimus-eluting airway stent reduces profibrotic Th17 cells and inhibits laryngotracheal stenosis. *JCI Insight* 2023; 8: e158456.
16. Moroni L, Giudice L, Lanzillotta M, Cariddi A, Ramirez GA, Bozzolo EP et al. Role of systemic immunosuppression on subglottic stenosis in granulomatosis with polyangiitis: analysis of a single-centre cohort. *Eur J Intern Med* 2023; 114: 108-12.
17. Monach PA. L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener's). *Presse Med* 2013; 42: 575-6.
18. Aden AA, Awadallah AS, Xie KZ, Wallerius KP, O'Byrne TJ, Bowen AJ, et al. Medical maintenance therapy following laser excision in patients with granulomatosis with polyangiitis (GPA)-associated subglottic stenosis. *Otolaryngol Head Neck Surg* 2024; 171: 180-7.
19. Almuhanha A, Almahboob A, Alhussien A, Aljurayyed R, Alammam A. Current therapeutic approaches to subglottic stenosis in patients with GPA: a systematic review. *Ear Nose Throat J* 2024; 103: 117-25.




Figure 1. Image from the rhinofibroscopic evaluation performed after 12 months of treatment with sirolimus that showed stable subglottic stenosis in the absence of new lesions.




Figure 2. Subglottic stenosis is evidenced in the computed tomography scan performed in 2022 (A) and after treatment in 2024 (B).